Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
461-480 of 847 trials

Breast Cancer: Abemaciclib with Endocrine Therapy

We are studying a combination of Abemaciclib and endocrine therapy for patients with advanced hormone receptor positive HER2 negative breast cancer. The trial focuses on how well this treatment works and how we can manage side effects using digital tools.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cholestatic Pruritus: Maralixibat Study

We are testing a new medication, maralixibat, for individuals with cholestatic pruritus to see if it can reduce itching and lower bile acid levels in the blood.

Cholestatic PruritusConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteDermatologyHepatology

Amyotrophic Lateral Sclerosis: ARGX-119 Study

We are testing a new treatment called ARGX-119 for adults with ALS to see if it is safe and how well it works in slowing disease progression.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Non-Small Cell Lung Cancer: BAY 2927088 Study

We are investigating how well BAY 2927088 works and its safety compared to standard treatment for patients with advanced non-small cell lung cancer with HER2 mutations.

Advanced Non-Small Cell Lung Cancer with HER2 MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sasanlimab for Muscle Invasive Bladder Cancer

We are studying whether sasanlimab can help patients with muscle invasive bladder cancer keep their bladder intact after initial treatment. The trial looks at survival rates and quality of life for participants.

Invasive Bladder Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Hidradenitis Suppurativa: Sonelokimab Treatment Study

We are testing a new injectable medication, sonelokimab, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it can improve symptoms compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyDermatology

Community-Acquired Pneumonia: Inhaled Levofloxacin Study

We are investigating whether inhaling levofloxacin helps improve health in patients with community-acquired pneumonia. This study includes individuals with and without pre-existing lung disease.

Community-acquired Pneumonia>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesInfectious DiseasesPulmonology

Hepatocellular Carcinoma: Triple Treatment Study

We are studying a combination of three medications for patients with non-resectable liver cancer. The goal is to see if this approach improves symptoms and quality of life compared to past treatments.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Rheumatoid Arthritis: Baricitinib and Anti-TNF Combination Study

We are investigating whether combining baricitinib with anti-TNF therapy helps patients with rheumatoid arthritis who haven't responded to other treatments. The study will also look at safety and how well patients can reduce their steroid use.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Fibrodysplasia Ossificans Progressiva: Fidrisertib Study

We are studying a new oral medication for people with fibrodysplasia ossificans progressiva to see if it can help prevent new bone growth and improve overall health. This trial includes both children and adults to evaluate its safety and effectiveness.

Fibrodysplasia Ossificans ProgressivaEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurology

Crohn's Disease in Children: Mirikizumab Study

We are studying whether Mirikizumab can help children with moderately to severely active Crohn's Disease achieve better health compared to a placebo. This research aims to improve treatment options for young patients.

Crohn's Disease1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Chronic Myeloid Leukemia: Olverembatinib Study

We are testing a new drug, Olverembatinib, for patients with Chronic Phase Chronic Myeloid Leukemia. The study aims to see if it works better than the current treatment, Bosutinib, especially for those with a specific mutation.

Chronic Myeloid Leukemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Breast Cancer: Alisertib with Hormone Therapy

We are studying how well alisertib works with hormone therapy for patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. Our goal is to find the best dose and assess safety and effectiveness.

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Rheumatoid Arthritis: Abatacept and Daratumumab Treatment

We are studying a combination of two medications to see if it is safe and effective for people with rheumatoid arthritis who have specific antibodies. This research aims to explore new ways to manage autoimmunity in these patients.

Rheumatoid Arthritis6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Myelofibrosis: Tasquinimod Treatment Study

We are studying tasquinimod in patients with myelofibrosis who are not responding to current treatments. The goal is to see if it can safely reduce spleen size and improve symptoms.

Myelofibrosis3-6 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Multiple Sclerosis in Kids: Ofatumumab and Siponimod Study

We are comparing two new treatments, ofatumumab and siponimod, to fingolimod in children with multiple sclerosis. The study aims to see if these new options are as effective and safe for managing their condition.

Multiple Sclerosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Kidney Disease: Frexalimab, Brivekimig, and Rilzabrutinib Study

We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Immune System Diseases1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNephrology